Sarepta Therapeutics Income Statement - Quarterly (NASDAQ:SRPT)

Add to My Stocks
$36.26 $1.54 (4.44%) SRPT stock closing price Apr 28, 2017 (Closing)

Fundamental analysis of SRPT stock involves analyzing its financial statements, apart from checking the Sarepta Therapeutics stock price In the income statement, an investor can look at important parameters like revenue, gross profits, net profits, and EPS basic to gain deeper insights. The income statement for SRPT which implies a QoQ revenue growth of $5.42M is specific to a period of time. Investors typically check YoY or QoQ revenue growth. The operating expenses (also check: Sarepta Therapeutics assets and Sarepta Therapeutics free cash flow) as shown in the Sarepta Therapeutics profit and loss statement 2016-Q4 total to $93.69M. This line item has increased from $56.52M compared with last quarter. View details of revenue and profits for Sarepta Therapeutics for latest & last 40 quarters.

show more
Annual
Quarterly
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec. 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3
Sarepta Therapeutics Net Sales or Revenues
5.42M---1.25M---0.03M1.06M
Cost Of Goods Sold (COGS)----------
Sarepta Therapeutics Gross Profit
----1.25M---0.04M1.05M
Research & Development Expense70.75M34.34M-38.82M41.38M36.67M29.18M39.16M30.84M21.85M
Selling General & Admin Expense22.94M22.18M-20.87M24.34M15.09M12.92M22.69M13.92M12.88M
Income Before Depreciation Depletion Amortization-93.69M-56.53M--59.7M-64.46M-51.76M-42.1M-61.86M-44.72M-33.67M
Depreciation Depletion Amortization----------
Non Operating Income-0.06M-0.2M--0.06M-0.23M-0.17M0.25M0.3M0.31M4.44M
Interest Expense----------
Sarepta Therapeutics Pretax Income
-88.45M-56.74M--59.77M-64.7M-51.93M-41.85M-61.55M-44.42M-29.22M
Provision for Income Taxes----------
Minority Interest----------
Investment Gains Losses----------
Other Income----------
Income Before Extraordinaries & Disc Operations-88.45M-56.74M-62.3M-59.77M-64.68M-51.94M-41.85M-61.56M-44.42M-29.23M
Extraordinary Items & Discontinued Operations----------
Sarepta Therapeutics Net Income (Profit/Loss)
-88.45M-56.74M-62.3M-59.77M-64.68M-51.94M-41.85M-61.56M-44.42M-29.23M
Average Shares used to compute Diluted EPS54.62M48.25M46.16M45.7M44.88M41.57M41.36M41.32M41.3M41.07M
Average Shares used to compute Basic EPS54.62M48.25M46.16M45.7M44.88M41.57M41.36M41.32M41.3M41.07M
Income Before Nonrecurring Items-86.31M-52.8M-61.68M-59.77M-64.68M-51.94M-41.85M-61.56M-44.41M-33.48M
Income from Nonrecurring Items-2.14M-3.94M-0.63M------4.26M
Sarepta Therapeutics Earnings Per Share Basic Net
-1.62-1.18-1.35-1.31-1.44-1.25-1.01-1.49-1.08-0.71
Sarepta Therapeutics Earnings Per Share Diluted Net
-1.62-1.18-1.35-1.31-1.44-1.25-1.01-1.49-1.08-0.71
EPS Diluted Before Nonrecurring Items-1.58-1.10-1.34-1.31-1.44-1.25-1.01-1.49-1.08-0.81
Preferred Dividends Acc Pd----------
Dividends Common----------
Dividend Per Share Common----------
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters
Get Income statement for another ticker

1:11
SRPT
Sarepta Therapeutics stock analysis involves checking at least a few of the important things like:
  • Top line: The word topline comes from the fact that the first line of an income statement refers to sales numbers. If you check you will find that SRPT stock has a topline or revenue of $5.42M for 2016-Q4 as per this Sarepta Therapeutics revenue chart. Investors look for stocks with a growing top line.
  • Bottom line: The Bottomline or the net income figure is arrived at by deducting all expenses from the topline which in this case is $5.42M - other expenses = $-88.45M for SRPT stock. An improving bottomline implies that the company is growing profits.
The income statement is also called statement of revenue and expense. The financials along with Sarepta Therapeutics historical stock prices provides a lot of details about the firm. .

Sarepta Therapeutics Income Statement - Key Financial Ratios

Operating margin
-1728.6
Net profit margin
-1631.9

Other Income Statements - Sarepta Therapeutics Inc Industry Peers

Aviragen Therapeutics income statement, BioCryst Pharma income statement, Blueprint Medicines income statement, Gilead Sciences income statement, Halozyme Therapeutics income statement